Dexcom Finishes Off Class Claims Over Sales Growth Statements

Dexcom convinced a federal judge that its phrasing about market share in two statements about sales growth for certain glucose monitors wasn’t misleading, winning the dismissal of remaining claims in a securities suit.

Judge Robert S. Huie of the US District Court for the Southern District of California had previously allowed two misrepresentation claims to survive, both related to Dexcom’s assurances that it was “taking share” of the market for glucose monitors used by Type 2 diabetes patients taking basal insulin. But a new hypothetical example presented by Dexcom convinced him to grant the company’s request for judgment on the ...